Larimar Therapeutics, Inc. (LRMR) Stock Price & Analysis

Larimar Therapeutics, Inc. (LRMR) is trading at USD 3.23, up 7.86% today, as of November 18, 2026 at 20:43 UTC (US market open; quotes may be delayed), according to Nexqual market data.

LRMR last closed at USD 3.23; today's session has ranged USD 2.93–3.35 on volume of 1,190,164 shares. Market capitalization is —, with a 52-week range of USD 1.92–6.42 (NGM). Source: Nexqual, retrieved November 18, 2026 at 20:43 UTC.

What changed for LRMR since Aug 31, 2025

The built-in knowledge of several widely used AI models ends around Aug 31, 2025. Everything below is newer, dated and sourced (as of Nov 18, 2026).

Also available as compact Markdown for AI agents: nexqual.com/LRMR.md

Key facts (LRMR)

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (LRMR)

USDFY2021FY2022FY2023FY2024FY2025TTM
Operating income-$50.5M-$36.5M-$41.8M-$90.9M-$172M-$162M
Net income-$50.6M-$35.4M-$36.9M-$80.6M-$166M-$156M
EPS (diluted)-$2.95-$1.37-$0.84-$1.32——
Free cash flow-$42.4M-$27.7M-$33.6M-$71.3M-$113M—
Cash + short-term investments—$118M$86.8M$184M$137M—

Fiscal years end Dec. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Sep 30, 2026) (LRMR)

P/B 3.3x · Earnings yield -46.53%

Analysts (LRMR)

Rating changes, last 120 days:

DateFirmActionRatingPrice target
2026-08-05WedbushTarget loweredOutperform$12 → $11

Total return (dividends reinvested) (LRMR)

1Y (from 2025-11-18)5Y (from 2021-11-15)
Total return-4.9%-68.5%
S&P 500 (SPY)+11.9%+66.7%
Per year-4.9%-20.6%
Volatility (annualized)93.5%95.2%
Max drawdown-66.6% (Feb 2026→Oct 2026)-86.1% (Dec 2021→Aug 2022)

Dividends (LRMR)

LRMR paid no cash dividend in the last five years.

Short interest (LRMR)

10,538,346 shares sold short, 15.50% of the float, as of Oct 30, 2026 (exchange short-interest report, published about twice a month). Prior report (Sep 30, 2026): 15,369,771 shares (-31.4%). Days to cover: 7.1 (short shares ÷ average daily volume).

LRMR earnings history and stock reaction

Results filedQuarterEPSConsensusSurpriseStock reaction
Nov 16, 2026Quarter ended Sep 30, 2026−$0.29−$0.36Beat +19.4%-1.0%
Nov 9, 2026Quarter ended Sep 30, 2026−$0.29−$0.36Beat +19.4%+12.6%
Aug 4, 2026Quarter ended Jun 30, 2026−$0.30−$0.38Beat +21.1%+3.0%
May 14, 2026Quarter ended Mar 31, 2026−$0.31−$0.59Beat +47.5%-12.7%
Mar 19, 2026Quarter ended Dec 31, 2025−$0.73−$0.55Miss −32.7%+4.4%
Jan 12, 2026Quarter ended Dec 31, 2025−$0.73−$0.55Miss −32.7%+0.0%
Nov 5, 2025————-8.7%
Aug 14, 2025————+7.8%

EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).

LRMR recent SEC filings (last 120 days)

FiledFormWhat it says
Nov 16, 202610-QQuarterly report · period ended Sep 30, 2026
Nov 16, 2026Schedule 13GRTW Investments, LP, Roderick Wong: 5.6% of shares, passive 5%+ holder
Nov 16, 20268-KQuarterly results
Nov 9, 20268-KQuarterly results; Other material event
“Press Release On November 9, 2026, the Company issued a press release announcing that the Company completed its rolling Biologics License Application submission to the U.S. Food and Drug Administration seeking accelerated approval of nomlabofusp for the treatment of patients with Friedreich's ataxia. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. Corporate Presentation On November 9, 2026, the Company posted on its website an…”
Sep 29, 20268-KDirector or executive officer change, or pay arrangement
“The Board of Directors (the "Board") of Larimar Therapeutics, Inc. (the "Company") appointed John B. Harlow, Jr. as the Company's President and Chief Operating Officer pursuant to the terms of an employment agreement with Mr. Harlow (the "Employment Agreement"), effective as of September 29, 2026 (the "Effective Date"). Prior to joining the Company, Mr. Harlow, age 51, served as the Chief Commercial Officer at Esperion Therapeutics, Inc. (formerly Nasdaq: ESPR), a commercial stage biopharmaceutical company focused…”
Aug 4, 202610-QQuarterly report · period ended Jun 30, 2026
Aug 4, 20268-KQuarterly results; Other material event
“On August 4, 2026, the Company posted on its website an updated slide presentation, which is attached as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference. Representatives of the Company will use the presentation in various meetings with investors, analysts and other parties from time to time.”

Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.

LRMR suppliers, customers and competitors (named in its 10-K)

RelationshipCompanySentence in the filing
SupplierKBI Biopharma“The drug substance which is in frozen liquid form for nomlabofusp is currently manufactured for us by KBI Biopharma, Inc. ("KBI").”
SupplierLonza“Additional comparability of the drug substance manufactured by Lonza will need to be performed and reviewed by the FDA and other regulatory authorities in order to use the Lonza-manufactured drug substance in clinical and commercial activities.”

Quoted from the company's 10-K filed Mar 19, 2026.

Companies that name LRMR in their SEC reports

Relationship to LRMRCompanyFilingSentence
partnerLexeo Therapeutics, Inc. (LXEO)10-K Mar 30, 2026“With respect to LX2006, we are aware of clinical stage gene therapy programs in development at Solid Biosciences Inc. and those being developed in collaborations between Voyager Therapeutics, Inc. and Neurocrine Biosciences, Inc. Among other treatment modalities for FA, we are aware that Larimar Therapeutics, Inc. is developing a clinical stage product candidate, CTI-1601, and that PTC Therapeutics, Inc. is evalua…”

LRMR company outlook (results filed Nov 16, 2026)

Quoted word-for-word from the SEC 8-K results press release.

LRMR analyst estimates and revisions

PeriodEPS estimate90 days agoChangeRevenue estimateAnalysts
Current quarter (ends Dec 2026)$-0.33$-0.38+$0.05$06
Next quarter (ends Mar 2027)$-0.36$-0.39+$0.03$04
Current fiscal year (ends Dec 2026)$-1.18$-1.35+$0.17$04
Next fiscal year (ends Dec 2027)$-0.91$-1.06+$0.15$38.8M8

LRMR options: expected move

ExpirationDaysATM implied volatilityExpected move
Nov 20, 20262262.1%±38.1%
Dec 18, 202630171.6%±34.8%
Jan 15, 20275890.0%±43.9%
Feb 19, 20279394.5%±42.1%

30-day implied volatility 86.4% vs 113.9% realized over the last 30 trading days. Put/call ratio (volume) 0. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.

Key Statistics (as of November 18, 2026 at 20:43 UTC)

PriceUSD 3.23
Change▲ 7.86% (up)
Previous CloseUSD 3.23
OpenUSD 3.23
Day RangeUSD 2.93 – 3.35
52-Week RangeUSD 1.92 – 6.42
Volume1,190,164 shares
Market Cap—
ExchangeNGM

Technical Analysis (LRMR)

Nexqual's technical model rates LRMR "BUY" based on 5 bullish and 2 bearish signals across 129 daily candles, as of November 18, 2026 at 20:43 UTC.

Overall SignalBUY
RSI (14)62.99 (neutral)
vs SMA50Above (USD 2.88)
MACD0.08 (positive)

Earnings (LRMR)

Next Earnings Date2026-11-16
EPS EstimateUSD -0.33
Revenue Estimate$0

Recent Earnings History

QuarterActual vs Estimate
2026-09-30USD -0.29 vs est -0.36 ▲ beat
2026-06-30USD -0.3 vs est -0.38 ▲ beat
2026-03-31USD -0.31 vs est -0.6 ▲ beat
2025-12-31USD -0.73 vs est -0.55 ▼ miss

Source: Nexqual, November 18, 2026 at 20:43 UTC.

Financials & Fundamentals (LRMR)

Gross Margin+0.00%
Operating Margin+0.00%
Profit Margin+0.00%
ROE-129.75%
Debt / Equity0.05
Current Ratio3.82
Total Cash$128.66M
Total Debt$4.78M

Source: Nexqual, November 18, 2026 at 20:43 UTC.

Financial Health Score (LRMR)

Nexqual rates Larimar Therapeutics, Inc.'s overall financial health "Mixed" across five dimensions, as of November 18, 2026 at 20:43 UTC.

GrowthMixed — No data
ProfitabilityWeak — Pre-revenue or very early stage
Balance SheetStrong — $129M cash vs $5M debt, net cash position
Cash FlowWeak — Operating cash flow -$113M (FY ended Dec 2025, 10-K)
EfficiencyCritical — ROE -154%, ROA -111.0% (last 4 quarters, SEC)

Ownership (LRMR)

Insider Ownership+1.26%
Institutional Ownership+101.09%
Shares Outstanding104.63M
Float57.15M
Short % of Float+15.50%

Source: Nexqual, November 18, 2026 at 20:43 UTC.

From Larimar Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-19)

Key Strengths & Strategy (as disclosed to the SEC)

Partnerships

Legal & Regulatory Risks (Item 1A, quoted)

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

SymbolNamePriceChange
KODKodiak Sciences IncUSD 98.14▲ 1.38%
BLTEBelite Bio, IncUSD 157.14▼ 0.37%
IBRXImmunityBio, Inc.USD 6.71▲ 7.19%
ORKAOruka Therapeutics, Inc.USD 95.92▼ 0.42%
IMVTImmunovant, Inc.USD 33.3▲ 0.27%
CGONCG Oncology, Inc.USD 79.9▲ 1.22%

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: November 18, 2026 at 20:43 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt